H H Lundbeck A-S
H
Suletud
41.78 2.1
Ülevaade
Aktsiahinna muutus
24h
Min
40.92
Max
41.8
Sissetulek | 1.7B 1.7B |
|---|---|
Müük | 1.2B 7B |
P/E Sektori keskmine | 10.766 68.51 |
Aktsiakasum | 1.671 |
Dividenditootlus | 2.85 |
Kasumimarginaal | 23.601 |
Töötajad | 5,000 |
EBITDA | 1.1B 2.8B |
Dividenditootlus Sektori keskmine | 2.85% 2.29% |
|---|
Turukapital | -1.8B 40B |
|---|---|
Eelmine avamishind | 39.68 |
Eelmine sulgemishind | 41.78 |
H Lundbeck A-S Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
H Lundbeck A-S Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest H Lundbeck A-S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
